|Articles|December 8, 2020

MHE Talks: Improving Patient Access with Kevin Lewis of Community Health Options

Author(s)Briana Contreras, Peter Wehrwein

MHE's Peter Wehrwein speaks with Kevin Lewis, president and CEO of Community Health Options in Maine. The two discussed how Community Health Options is improving patient access through telehealth and more services on Tuning Into The C-Suite's newest series MHE Talks: Improving Patient Access.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

MHE Talks: Improving Patient Access with Kevin Lewis of Community Health Options

Newsletter

Related Content

MHE Talks: Joe Gagnon and Don Rucker of 1upHealth Address How FHIR is Personalizing Healthcare

MHE Talks: Wes Gilson of Siemens Healthineers Addresses How Crucial Improving Access to MRI is to Advancing Health Equity

Christopher Crow, M.D., MBA, of Catalyst Health Network on Patient Access and PCMHs, Clinically Integrated Networks, and Medicaid Expansion in Texas

ICER Chief on Bempedoic Acid and Inclisiran: Don’t Repeat the PCSK9 Mistake

A Seat at the Table? No. Equity Means Changing the Shape of the Table.

Latest CME

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New Mexico

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Wisconsin

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Kentucky

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Indiana

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Community Oncology Connections ™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Missouri

Community Oncology Connections ™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | New Mexico

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | North Carolina

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Community Oncology Connections ™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Texas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

2nd Annual Hawaii Cancer Conference

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

22nd Annual Winter Lung Cancer Conference®

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

26th Annual International Lung Cancer Congress

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

20th Annual New York Lung Cancers Symposium®

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

27th Annual International Lung Cancer Congress®

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Missouri

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | West Virginia

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Tennessee

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Washington

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kentucky

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

21st Annual New York Lung Cancers Symposium®

9th Annual School of Nursing Oncology™

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

23rd Annual Winter Lung Cancer Conference®

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Trending on Managed Healthcare Executive

IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025

Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025

Jaypirca shows promise as a frontline treatment for CLL/SLL patients | ASH 2025

Venclexta combination improves survival and lowers hospital stays for AML patients | ASH 2025

Early findings suggest linvoseltamab could be a useful new option for new multiple myeloma patients | ASH 2025